Estimating direct costs of the treatment for mucosal leishmaniasis in Brazil
Rev. Soc. Bras. Med. Trop
; 54: e04542020, 2021. tab
Article
en En
| LILACS
| ID: biblio-1155531
Biblioteca responsable:
BR1.1
ABSTRACT
Abstract INTRODUCTION:
The objective of this study was to estimate the direct medical costs of the treatment for mucosal leishmaniasis (ML) using three therapeutic approaches in the Brazilian context.METHODS:
We performed this economic assessment from the perspective of the Brazilian public healthcare system. The following therapeutic approaches were evaluated meglumine antimoniate, liposomal amphotericin B, and miltefosine. Direct medical costs were estimated considering four treatment components a) drug, b) combined medical products, c) procedures, and d) complementary tests.RESULTS:
Treatment with meglumine antimoniate had the lowest average cost per patient (US$ 167.66), followed by miltefosine (US$ 259.92) in the outpatient treatment regimen. The average cost of treatment with liposomal amphotericin B was US$ 715.35 both in inpatient regimen. In all estimates, the drugs accounted for more than 60% of the total cost for each treatment approach.CONCLUSIONS:
These results demonstrate the marked differences in costs between the therapeutic alternatives for ML. In addition to efficacy rates and costs related to adverse events, our data have the potential to support a complete cost-effectiveness study in the future. Complete analyses comparing costs and benefits for interventions will assist health managers in choosing drugs for ML treatment in Brazil as well as in establishing effective public health policies.Palabras clave
Texto completo:
1
Índice:
LILACS
Asunto principal:
Leishmaniasis Mucocutánea
/
Antiprotozoarios
Tipo de estudio:
Health_economic_evaluation
Límite:
Humans
País/Región como asunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Rev. Soc. Bras. Med. Trop
Asunto de la revista:
MEDICINA TROPICAL
Año:
2021
Tipo del documento:
Article